{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:50:44Z","timestamp":1790142644814,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102181","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:42:01Z","timestamp":1590010921000},"page":"102181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0402","authenticated-orcid":false,"given":"Elizabeth R.","family":"Comini-Frota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Pontes Freitas","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Pereira Gomes","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-5243","authenticated-orcid":false,"given":"Paulo Pereira","family":"Christo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102181_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ene.12798","article-title":"A basic overview of multiple sclerosis immunopathology","volume":"22","author":"Grigoriadis","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102181_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.102181_bib0003","article-title":"Alemtuzumab for multiple sclerosis","volume":"4","author":"Riera","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2020.102181_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2020.102181_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102181_bib0006","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102181_bib0007","doi-asserted-by":"crossref","first-page":"e2233","DOI":"10.1212\/WNL.0000000000006648","article-title":"Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells","volume":"91","author":"Ruck","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102181_bib0008","first-page":"bcr","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2020.102181_bib0009","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.msard.2018.11.029","article-title":"Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report","volume":"27","author":"Pisa","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102181_bib0010","doi-asserted-by":"crossref","first-page":"bcr","DOI":"10.1136\/bcr-2018-226588","article-title":"Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis","volume":"2018","author":"Madeley","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2020.102181_bib0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: Update review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.msard.2020.102181_bib0012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.20452\/pamw.2192","article-title":"Acquired hemophilia A: an underdiagnosed, severe bleeding disorder","volume":"124","author":"Zdziarska","year":"2014","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.msard.2020.102181_bib0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2020.102181_bib0014","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2020.102181_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:35Z","timestamp":1761900635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820302571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":15,"alternative-id":["S2211034820302571"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102181","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102181"}}